Tadalafil

phosphodiesterase 5A ; Homo sapiens







301 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
51 26551887 The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma. 2016 Jan 28 2
52 26620458 Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. 2016 Sep-Oct 1
53 26676726 [Pharmacological treatment of benign prostatic hyperplasia]. 2016 Jan 1
54 27337189 Isolation and structural characterization of a new tadalafil analog (chloropropanoylpretadalafil) found in a dietary supplement. 2016 Sep 5 1
55 27418235 Inhibition of Adrenergic and Non-Adrenergic Smooth Muscle Contraction in the Human Prostate by the Phosphodiesterase 10-Selective Inhibitor TC-E 5005. 2016 Nov 1
56 27440770 BET 2: Tadalafil medical expulsive therapy in ureteral calculi: a new kid on the block? 2016 Aug 2
57 27871960 Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors. 2016 Jul 1
58 27928428 Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. 2016 Aug 1
59 28163539 Inhibition by tadalafil of contractility of isolated nonpregnant human myometrium. 2016 Oct-Dec 1
60 25318865 Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. 2015 Feb 2
61 25320361 Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. 2015 Jan 1 1
62 25352458 Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension. 2015 Jan 2
63 25444755 PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. 2015 Mar 4
64 25462127 Isolation and structural characterization of a new tadalafil analog (2-hydroxyethylnortadalafil) found in a dietary supplement. 2015 Jan 25 1
65 25564570 Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. 2015 Jan 1 1
66 25744459 Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. 2015 2
67 25801159 Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5. 2015 May 1 1
68 25981401 Effects of phosphodiesterase-5 inhibitor on ischemic kidney injury during nephron sparing surgery: quantitative assessment by NGAL and KIM-1. 2015 Dec 2
69 26047999 [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. 2015 Jul-Sep 1
70 26060141 Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings. 2015 Aug 1
71 26161145 Tadalafil therapy for erectile dysfunction following prostatectomy. 2015 Jun 1
72 26328208 Current use of phosphodiesterase inhibitors in urology. 2015 Jun 1
73 26425140 Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. 2015 Oct 2
74 26962606 2015 Jul 2
75 23721687 Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges. 2014 Jan 1
76 23841532 A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. 2014 Mar 5
77 24271647 Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. 2014 Feb 2
78 24341303 Tadalafil - a therapeutic option in the management of BPH-LUTS. 2014 Jan 3
79 24666765 Effect of once-daily tadalafil on confidence and perceived difficulty in performing sexual intercourse in men who were incomplete responders to as-needed PDE5 inhibitor treatment. 2014 Jul 1
80 24717626 Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. 2014 Apr 1
81 24796952 Analysis of illicit dietary supplements sold in the Italian market: identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. 2014 May 2
82 24808022 PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. 2014 Jun 10 1
83 24878583 Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. 2014 Aug 1
84 24940471 Sildenafil can induce the onset of a cluster headache bout. 2014 May 1
85 25140232 Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. 2014 1
86 25178687 Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension. 2014 Nov 1
87 25202655 Can selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphadiesterase type 5 (PDE 5) offer protection against contrast induced nephropathy? 2014 Aug 2
88 25322707 Tadalafil prevents acute heart failure with reduced ejection fraction in mice. 2014 Dec 1
89 26583228 Ab Initio QM/MM Study Shows a Highly Dissociated SN2 Hydrolysis Mechanism for the cGMP-Specific Phosphodiesterase-5. 2014 Dec 9 1
90 22971615 Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency. 2013 Jan 1
91 23065016 Central serous chorioretinopathy due to tadalafil use. 2013 Apr 1
92 23253640 Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction. 2013 Jul 1
93 23312193 Re: combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-responders with severe and intermediate testosterone deficiency. 2013 Feb 1
94 23369145 Managing erectile dysfunction in heart failure. 2013 Mar 1
95 23372609 Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. 2013 Feb 2
96 23386068 Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. 2013 Feb 1
97 23417046 [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors]. 2013 Feb 2
98 23441682 Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction. 2013 May 1
99 23512808 Title efficacy of phosphodiesterase 5 inhibitor on distant burn-induced muscle autophagy, microcirculation, and survival rate. 2013 May 1 1
100 23529917 Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. 2013 Jun 1